Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $24 price target on Moderna, which he calls "the leading developer of messenger RNA therapeutics." The analyst noted that Moderna ended 2018 with cash of around $1.7B, and said he is looking for clinical data and progress to drive value in 2019.

Moderna announced a contract with the Ministry of Health in Brazil to supply its mRNA COVID-19 vaccine as an integral part of Brazil's 2024 national vaccination campaign against COVID-19. This contract follows the Brazilian Health Regulatory Agency's approval of Moderna's COVID-19 vaccine in March 2024, which encodes the spike protein of the XBB.1.5 sublineage of SARS-CoV-2 for active immunization for the prevention of COVID-19 in children from six months of age and adults. Under the contract, 12.5 million doses of Moderna's mRNA COVID-19 vaccine are anticipated for delivery in the second quarter of 2024, marking a significant milestone in Brazil's ongoing efforts to combat COVID-19. The partnership between Moderna and the Ministry of Health reflects a shared commitment to public health and the importance of national immunization campaigns. This contract is expected to bolster Brazil's national vaccination campaign and contribute to the global effort to combat the enduring threat of COVID-19.